Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 6/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | DRD4 | P21917 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17350847 | 1.00 | HCRTR2 (0.40) | HCRTR2HCRTR1SLC18A3SIGMAR1HRH3 | |
| SCHEMBL10243778 | 0.79 | SLC18A3 (0.44) | HCRTR2HCRTR1SLC18A3SIGMAR1HRH3 | |
| SCHEMBL17350871 | 0.79 | SLC18A3 (0.44) | HCRTR2HCRTR1SLC18A3SIGMAR1HRH3 | |
| SCHEMBL17350960 | 0.78 | HSD11B1 (0.50) | SLC18A3SIGMAR1HRH3SPRDRD2 | |
| SCHEMBL10243863 | 0.78 | HSD11B1 (0.50) | SLC18A3SIGMAR1HRH3SPRDRD2 | |
| SCHEMBL17350818 | 0.77 | SLC18A3 (0.49) | HCRTR2HCRTR1SLC18A3SIGMAR1HRH3 | |
| SCHEMBL10244093 | 0.77 | SLC18A3 (0.49) | HCRTR2HCRTR1SLC18A3SIGMAR1HRH3 | |
| SCHEMBL10243883 | 0.76 | POLB (0.57) | SLC18A3SIGMAR1HRH3DRD2DRD4 | |
| SCHEMBL17350984 | 0.76 | POLB (0.57) | SLC18A3SIGMAR1HRH3DRD2DRD4 | |
| SCHEMBL10243880 | 0.75 | POLB (0.51) | SLC18A3SIGMAR1HRH3DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318403-B1 | Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INT (DE) | 2015-12-23 | — | — | EP | disclosed |
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115853-A1 | Aryl- and Heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use | HSD11B1, HSD11B2, HSD17B1 | HCRTR2 932/4885HCRTR1 1235/4885SLC18A3 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.